SCHEMBL4294182

SCHEMBL4294182

O=C(O)C1(CO)CCNCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.37
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 1/20 0.33
OPRM1 P35372 1/20 0.32
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31
SLC6A3 Q01959 2/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
GABRA1 P14867 1/20 0.31
TSHR P16473 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRB2 P47870 1/20 0.31
GABRA4 P48169 1/20 0.31
GABRE P78334 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092643 0.86 SLC6A2 (0.37) CYP2C19SLC6A2SLC6A4SLC6A3ARG1
SCHEMBL252560 0.82 CYP2C19 (0.44) CYP2C19
SCHEMBL1815192 0.82
SCHEMBL7370249 0.79 KDM4E (0.36) CYP2C19KDM4EKMT2AOPRM1SLC6A2
SCHEMBL27522485 0.79 CYP2C19 (0.35) CYP2C19KDM4EKMT2AOPRM1SLC6A2
SCHEMBL26667126 0.79 CYP2C19 (0.61) CYP2C19KDM4EKMT2AOPRM1SLC6A2
SCHEMBL855051 0.79 OPRM1 (0.38) CYP2C19KDM4EKMT2AOPRM1SLC6A2
Hydrochloric Acid SCHEMBL26667139 0.77 CYP2C19 (0.59) CYP2C19KDM4EKMT2AOPRM1SLC6A2
SCHEMBL2277073 0.77 CYP2C19 (0.58) CYP2C19TSHR
SCHEMBL13898741 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149628-A1 PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE ASTRAZENECA AB (SE) 2025-07-17 WO disclosed
CN-114727993-A Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-08 CN disclosed
CN-103619838-B Piperidinyl monocarboxylic acids as S1P1 receptor agonists 生物计划公司 2016-08-24 CN disclosed
CN-102498099-B HSL inhibitors useful in the treatment of diabetes HOFFMAN-LA ROCHE LTD. (CH) 2014-10-29 CN disclosed
CN-103619838-A Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists BIOPROJET SOC CIV 2014-03-05 CN disclosed
CN-102498099-A HSL inhibitors useful in the treatment of diabetes HOFFMANN LA ROCHE 2012-06-13 CN disclosed
US-20090264466-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-22 US disclosed
CN-1163616-A DC107 derivatives KYOWA HAKKO KOGYO KK (JP) 1997-10-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264466-A1 Certain Chemical Entities, Compositions and Methods MYLK, MYH2, MYH10 CYP2C19 2274/4885KDM4E 3559/4885KMT2A 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.